Pfizer C4471001 (BRAF V600): Solid Tumors - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out what the safest and most effective dose of the study drug (PF-07284890) is when given alone or in combination with Binimetinib.
Advanced solid tumors (including primary brain)
Who Can Participate in the Study?
Adults with BRAF V600 mutant advanced solid tumors with and without brain involvement.
What is Involved?
If you choose to join this study you will:
-Take the study drug (PF-07284890) by mouth 1 to 2 times a day
-Have a full eye examination
-Have physical exams, blood and urine tests.
-Have imaging scans (CT and/or MRI)
Some people will also:
-Take Binimetinib by mouth 2 times a day